Peptide Biomarkers for Parkinson’s Disease
![Min Shi](/sites/pdbp/files/styles/square_crop/public/2021-06/Shi_Min%20%28002%29.jpg?h=f0c29ff4&itok=IEYhmXWb)
Summary
This proposal is designed to meet several major challenges of current biomarker research, specifically: 1) significant variations associated with antibody-based protein assays, 2) low sensitivity and specificity of blood based markers, and 3) detection of PD at early stages. To address the problems of antibody-based assays, the strategy used in this proposal will focus on the development of targeted mass spectrometry-based techniques, such as selected reaction monitoring (SRM), to validate peptide markers derived from proteins either replicated in previous proteomics profiling, or known to be critical to PD pathogenesis, e.g., α-synuclein, parkin and LRRK2 from cerebrospinal fluid and plasma-derived exosomes.